Mankind Pharma Ltd Sees Sharp Open Interest Surge Amid Bullish Market Momentum

Open Interest and Volume Dynamics

The latest data reveals that Mankind Pharma’s open interest in derivatives jumped from 21,071 contracts to 25,407, marking a substantial 20.58% increase. This rise in OI was accompanied by a volume of 31,981 contracts, indicating strong participation in the futures and options market. The futures segment alone accounted for a value of approximately ₹6,253.75 lakhs, while the options segment's notional value stood at an impressive ₹18,710.04 crores, culminating in a total derivatives value of ₹8,241.46 lakhs.

This surge in open interest, coupled with elevated volumes, suggests that market participants are actively positioning themselves, possibly anticipating further price movements. The underlying stock price closed at ₹2,398, having touched an intraday high of ₹2,400, representing a 4.32% rise on the day.

Price Performance and Technical Indicators

Mankind Pharma has been on a positive trajectory, registering gains for three consecutive sessions with a cumulative return of 6.79%. Today’s 4.83% increase notably outpaced the Pharmaceuticals & Biotechnology sector’s 1.26% gain and the broader Sensex’s modest 0.12% rise, underscoring the stock’s relative strength.

The stock opened with a gap-up of 4.28%, signalling strong buying interest from the outset. Despite trading within a narrow intraday range of ₹2.3, the weighted average price indicates that most volume was transacted near the lower end of this range, hinting at cautious accumulation rather than aggressive buying at peak prices.

From a technical standpoint, Mankind Pharma’s price currently sits above its 5-day, 20-day, and 200-day moving averages, reflecting short- and long-term bullish momentum. However, it remains below the 50-day and 100-day moving averages, suggesting some resistance levels yet to be overcome for a sustained uptrend.

Investor Participation and Liquidity

Investor engagement has notably increased, with delivery volumes on 18 September reaching 3.72 lakh shares, a 23.62% rise compared to the five-day average. This heightened delivery volume indicates genuine buying interest rather than speculative intraday trading, which often bodes well for price stability and future appreciation.

Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting transactions up to ₹2.51 crores without significant market impact. This level of liquidity is crucial for institutional investors and large traders looking to build or unwind positions efficiently.

Market Positioning and Potential Directional Bets

The pronounced increase in open interest alongside rising volumes typically signals fresh positions being established rather than existing ones being squared off. Given the concurrent price appreciation and gap-up opening, it is plausible that traders are adopting bullish stances on Mankind Pharma, anticipating further upside in the near term.

Options market data, with a notional value exceeding ₹18,710 crores, further supports the notion of active hedging and speculative activity. The large options value relative to futures suggests that market participants may be employing strategies such as call buying or bull call spreads to capitalise on expected upward price movements while managing risk.

However, the stock’s position below the 50-day and 100-day moving averages indicates that some resistance remains, and investors should monitor these technical levels closely. A decisive break above these averages could trigger a more sustained rally, while failure to do so might invite profit-taking or consolidation.

Mojo Score and Analyst Ratings

Mankind Pharma currently holds a Mojo Score of 50.0 with a Mojo Grade of Hold, reflecting a neutral stance from MarketsMOJO’s comprehensive evaluation. This represents a downgrade from a previous Buy rating as of 3 August 2026, signalling a more cautious outlook amid recent market developments.

The mid-cap pharmaceutical company, with a market capitalisation of approximately ₹98,536 crores, remains a significant player in its sector. While the recent price momentum and derivatives activity are encouraging, the Hold rating suggests investors should weigh potential risks and rewards carefully before increasing exposure.

Outlook and Investor Considerations

In summary, the sharp rise in open interest and volume in Mankind Pharma’s derivatives market, combined with strong price performance and increased delivery volumes, points to a bullish sentiment among traders. The stock’s outperformance relative to its sector and the broader market further reinforces this positive momentum.

Nonetheless, the Hold rating and technical resistance levels caution investors to remain vigilant. Monitoring the stock’s ability to sustain gains above key moving averages and observing changes in open interest patterns will be critical in assessing the durability of the current rally.

For investors considering exposure to Mankind Pharma, balancing the evident upside potential with the inherent volatility of mid-cap pharmaceutical stocks is essential. The evolving derivatives activity offers valuable insights into market positioning and can serve as a useful barometer for timing entries and exits.

Summary of Key Metrics:

• Open Interest increased by 20.58% to 25,407 contracts
• Volume at 31,981 contracts, indicating strong participation
• Futures value: ₹6,253.75 lakhs; Options value: ₹18,710.04 crores
• Stock price rose 4.83% to ₹2,398, outperforming sector by 3%
• Delivery volume up 23.62% to 3.72 lakh shares
• Mojo Grade downgraded from Buy to Hold on 3 August 2026

Investors should continue to analyse derivatives data alongside price action and fundamental developments to make informed decisions in this evolving market environment.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →